Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences' Trodelvy (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

11/24/2021 | 07:22am EST

FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan), a first-in-class Trop-2-directed antibody-drug conjugate, as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease.

'The metastatic stage of TNBC is particularly challenging to treat and until now we have urgently needed new treatment options for people in Europe living with this condition,' said Dr Veronique Dieras, Senior Medical Oncologist Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. 'Today's approval including second-line metastatic TNBC is significant for the community as it's another important step forward in helping women with this disease live longer.'

TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers. It is more frequently diagnosed in younger and premenopausal women and is more prevalent in Black and Hispanic women. The five-year survival rate for this sub-type of breast cancer is 12%, compared with 28% for other breast cancer types, and these poor outcomes are often coupled with a significant decrease in quality of life, especially in relapsed/refractory disease.

'At Gilead, we push boundaries to deliver transformative science and novel treatment options that address urgent medical needs,' said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. 'We understand how difficult metastatic TNBC is to treat and we're proud that Trodelvy can now offer a second-line treatment option with the potential to bring longer life to people living with this aggressive disease.'

The EC's decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician's choice of chemotherapy (HR: 0.51; 95% CI: 0.41-0.62; p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about GILEAD SCIENCES, INC.
01/26Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO
RE
01/26Gilead's Oncology Studies of Magrolimab-Azacitidine Drug Combination Placed on Partial ..
MT
01/25Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination..
BU
01/25Gilead Sciences Inc. Announces U.S. Food and Drug Administration Place Partial Clinical..
CI
01/25Sierra Oncology's bone marrow cancer drug meets study main goal
RE
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24Gilead Sciences-FDA Approves Veklury (Remdesivir) for the Treatment of Non-Hospitalized..
AQ
01/24Gilead Secures FDA Approval for Veklury in Non-Hospitalized COVID-19 Patients at High R..
MT
01/21Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
DJ
01/21FDA Approves Veklury« (Remdesivir) for the Treatment of Non-Hospitalized Patients at Hi..
BU
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 637 M - -
Net income 2021 7 225 M - -
Net Debt 2021 22 428 M - -
P/E ratio 2021 11,7x
Yield 2021 4,20%
Capitalization 84 470 M 84 470 M -
EV / Sales 2021 4,01x
EV / Sales 2022 4,16x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 67,34 $
Average target price 75,96 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812
BEIGENE, LTD.-17.13%23 067